AGWCA
CPRX

Annis Gardner Whiting Capital Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Annis Gardner Whiting Capital Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-36
Closed -$782 – 1241
2025
Q2 		$782 Buy
+36
New +$850 ﹤0.01% 1119

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Annis Gardner Whiting Capital Advisors's CPRX Position: Q3 2025 in Review

Annis Gardner Whiting Capital Advisors sold out of Catalyst Pharmaceutical (CPRX) in Q3 2025, closing a stake of 36 shares — an estimated $782 sold.

Annis Gardner Whiting Capital Advisors first reported a position in CPRX in Q2 2025 and held it in 1 quarter. The position peaked at $782 in Q2 2025. 360 funds tracked by Wall St. Rank hold CPRX as of Q3 2025.

  • Annis Gardner Whiting Capital Advisors reported no remaining Catalyst Pharmaceutical position as of Q3 2025 after selling out during the quarter.
  • Annis Gardner Whiting Capital Advisors sold 36 Catalyst Pharmaceutical shares in Q3 2025, an estimated $782.
  • Annis Gardner Whiting Capital Advisors first reported a position in Catalyst Pharmaceutical in Q2 2025 and held it in 1 quarter.
  • Annis Gardner Whiting Capital Advisors's Catalyst Pharmaceutical position peaked at $782 in Q2 2025.
  • 360 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2025.

Based on Annis Gardner Whiting Capital Advisors's 13F filing for Q3 2025, filed 3 Nov 2025.